Metsera (NASDAQ:MTSR) Trading Down 3.7% - Here's Why

Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s stock price dropped 3.7% during mid-day trading on Friday . The company traded as low as $27.61 and last traded at $27.61. Approximately 56,606 shares were traded during trading, a decline of 93% from the average daily volume of 862,642 shares. The stock had previously closed at $28.67.

Analyst Ratings Changes

Several equities research analysts recently commented on MTSR shares. Bank of America began coverage on Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating on the stock. Guggenheim started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price on the stock. Finally, Evercore ISI started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an "outperform" rating for the company.

Metsera Price Performance

The company's 50 day moving average price is $22.90.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MTSR. Rhumbline Advisers purchased a new position in Metsera during the first quarter valued at approximately $520,000. Strs Ohio purchased a new position in shares of Metsera during the 1st quarter valued at $76,000. Siren L.L.C. purchased a new position in shares of Metsera during the 1st quarter valued at $4,083,000. Woodline Partners LP bought a new position in Metsera in the 1st quarter worth $8,172,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Metsera in the 1st quarter worth $568,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.